WorksheetsTransition/Pioneer Study Quiz
Total questions: 20
Worksheet time: 40mins
What is the primary objective of the PIONEER-HF study?
Time-averaged proportional change in NT-proBNP concentration from baseline through Weeks 4 and 8
Composite endpoint of either death from cardiovascular causes, or a first hospitalization for heart failure
To evaluate the proportion of patients achieving the target dose of ENTRESTO 200 mg BID at Week 10 post-randomisation in the pre- and postdischarge treatment initiation groups
Safety and tolerability 3 week vs 6 week uptitration with Entresto
In the PIONEER-HF study, how much improvement was observed in the NT-pro BNP levels with Entresto vs enaapril?
46%
16%
21%
29%
In a pre-specified exploratory end point of PIONEER HF study, how much reduction was seen with Entresto vs enalapril in the risk of death, HF rehospitalisation, LVAD implantation, or listing for cardiac transplant?
21%
46%
29%
16%
PIONEER-HF and TRANSITION studies demonstrated the good safety and tolerability profile of Entresto, initiated shortly after stabilisation following an acute HF event.
TRUE
FALSE
NEITHER
How many patients were included in the PIONEER-HF study?
1002
8442
887
4002
What is the basis of dosage uptitration in the PIONEER-HF study?
DBP
SBP
BNP
NT-pro BNP
In the PIONEER-HF study, Entresto 200mg BID was compared to what drug?
Valsartan
Enalapril 10mg BID
Diuretic
Beta blocker
What is the study duration of PIONEER-HF?
8 weeks
10 weeks
12 weeks
16 weeks
Uptitration of dose was done in PIONEER-HF. Level 2 dose is defined as:
Entresto 50mg BID or enalapril 2.5mg BID
Entresto 100mg BID or enalapril 5mg BID
Entresto 200mg BID or enalapril 10mg BID
What type of patients were included in the PIONEER-HF study?
Out patient
Stabilized ADHF patients
Decompensated HF patients
All of the above
1.) HF is one the most common causes of hospitalization for patients aged < 65 years in developed countries.
TRUE
FALSE
2.) Hospitalization rates are comparable for patients with mild and moderate/
Severe HF ?
TRUE
FALSE
None of the above
Hospital admission for HF is a concrete opportunity to optimize HF therapy.
TRUE
FALSE
NEITHER
4.) In TRANSITION Study , down titration or temporary discontinuation of Entresto
Is allowed in all groups at any given time
TRUE
FALSE
BOTH answers are correct
What is the primary endpoint of Transition study?
Time-averaged proportional change in ntpro-
BNP concentration from baseline through week
4 and 8
Composite endpoint of either death from CV causes
Or first hospitalization.
Safety and tolerability 3 weeks vs 6 weeks uptitration
With Entreso
To evaluate the proportion of patient achieving the target
Dose of Entresto 200 mg BID at week 10 post randomization in the pre and post discharge treatment initiation groups.
6.) In Transition study , about half of patients with HF stabilized after ADHF event did not achieve the target dose of 200 mg Entresto BID within 10 weeks
TRUE
FALSE
EITHER
How many patients were included in Transition study ?
1002
8442
867
4002
1001
At week 10 , how many percent of patients were receiving Entresto at any dose for 2 weeks or lower without interruption.
86%
22%
46%
21%
Stable patient in Transition study is described as the following except
SBP of >/= 110 mmHg in the last 6 hrs
No IV vasodilators in the last 24 hrs
No need for IV diuretic in the last 24 hrs
SBP of >/= 100 mmHg in the last 6 hrs
What is the result of Transition study?
Comparable number of patients met the primary and secondary endpoints in the pre and post discharge initiaton group
29% reduction in NT probnp from baseline with Entresto vs Enalapril
Superiority of Entresto vs Enalapril in reducing CV death and hospitalization
